Exploiting pluripotent stem cell technology for drug discovery, screening, safety, and toxicology assessments☆
Graphical abstract
Section snippets
Introduction: rationale for use of stem cells for drug screening
Drug development is a multi-year, multi-million dollar proposition with the vast majority of promising compounds failing to come to fruition. Failure is likely not due to a lack of testable compounds as chemical libraries contain thousands of potentially therapeutic agents just waiting to be explored and scrutinized. Drug screening using in vitro cell culture systems provides the pharmaceutical industry a means to narrow down these large chemical libraries into a list of candidate compounds for
Targeted approach to drug discovery
Targeted and phenotypic approaches are two distinct methods for the identification of drug leads (Fig. 2; Table 1). A targeted approach focuses on identifying drugs that can interact with genes, gene products or molecular mechanisms [15], [16]. Therefore, a target based approach relies on what is known about a specific disease, and often requires that a specific mode of action is known, which is generally through the activation or inhibition of a receptor or channel (Fig. 2). The goal of a
Stem cells in safety pharmacology
The pharmaceutical industry generates large libraries of new chemical entities each year with the intent on identifying drugs that either interact with a chemical target or induce a desired physiological effect. When effective drugs are identified, further preclinical safety screening is necessary, both for the safety of the patients and to avoid large costs associated with failed clinical trials. Yet, even after exhaustive safety screening for proper adsorption, distribution, metabolism and
Disease modeling and drug screening
Much work has gone into identifying disease relevant defects in iPSC derived models that can be targeted for drug screening efforts. To date, most advances in cardiomyocyte drug screening have come in the form of toxicity screening rather than lead identification for specific cardiac related disease. However, iPSC derived cardiomyocytes have been used to evaluate the therapeutic efficacy potential of new and existing pharmacological agents. For example, Itzhake et al. generated iPSCs from
Challenges to PSC implementation in drug development
As demonstrated above many academic and industry laboratories have made substantial efforts toward developing systems for modeling human disease, exploring novel treatment paradigms, and testing the safety of current drugs using human PSCs. Despite these advances and the great promise PSC model systems provide, there is still much work to do. Some of the challenges moving forward include: 1) reducing cost, 2) standardizing HTS/HCS by reducing differentiation variability and enriching specified
Conclusions
The development of iPSC technology spurred the use of PSCs in disease modeling and drug exploration. As scientists begin to better understand the use of these cells and develop more reliable methods for differentiation, modeling, and screening, PSCs will likely aid the drug discovery process and reduce attrition rates. Though one must be aware of the challenges and caveats of using PSCs, recent advances and proof of concept retrospective studies provide the framework for improvements in drug
Acknowledgments
The authors thank Teresa Patitucci for providing artistic talent for figures and graphical abstract.
References (138)
- et al.
Shaker and ether-a-go-go K + channel subunits fail to coassemble in Xenopus oocytes
Biophys. J.
(1998) - et al.
Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics
Gastroenterology
(2006) - et al.
Properties of hERG channels stably expressed in HEK 293 cells studied at physiological temperature
Biophys. J.
(1998) - et al.
Induced pluripotent stem cells: a new revolution for clinical neurology?
Lancet Neurol.
(2011) - et al.
Caenorhabditis elegans as a chemical screening tool for the study o f neuromuscular disorders. Manual and semi-automated methods
Methods
(2012) - et al.
Phenotypic screens as a renewed approach for drug discovery
Drug Discov. Today
(2013) - et al.
A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells
Mol. Cell. Neurosci.
(2013) - et al.
Quantitative analyses of SMN1 and SMN2 based on real-time LightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy
Am. J. Hum. Genet.
(2002) - et al.
Nuclear gems and Cajal (coiled) bodies in fetal tissues: nucleolar distribution of the spinal muscular atrophy protein, SMN
Exp. Cell Res.
(2001) High content screening—from cells to data to knowledge
Drug Discov. Today
(2001)
High-throughput screening assay for the identification of compounds regulating self-renewal and differentiation in human embryonic stem cells
Cell Stem Cell
High-content screening for chemical modulators of embryonal carcinoma cell differentiation and survival
J. Biomol. Screen.
Small molecules efficiently direct endodermal differentiation of mouse and human embryonic stem cells
Cell Stem Cell
A small molecule primes embryonic stem cells for differentiation
Cell Stem Cell
Phenotypic screening with human iPS cell-derived cardiomyocytes: HTS-compatible assays for interrogating cardiac hypertrophy
J. Biomol. Screen.
Safety and secondary pharmacology: successes, threats, challenges and opportunities
J. Pharmacol. Toxicol. Methods
The significance of mitochondrial toxicity testing in drug development
Drug Discov. Today
The action potential and comparative pharmacology of stem cell-derived human cardiomyocytes
J. Pharmacol. Toxicol. Methods
The isolated rabbit heart and Purkinje fibers as models for identifying proarrhythmic liability
J. Pharmacol. Toxicol. Methods
The canine model with chronic, complete atrio-ventricular block
Pharmacol. Ther.
Beat-to-beat variability of repolarization as a new biomarker for proarrhythmia in vivo
Heart Rhythm
Assessment of beating parameters in human induced pluripotent stem cells enables quantitative in vitro screening for cardiotoxicity
Toxicol. Appl. Pharmacol.
Developing technologies to unlock the therapeutic and research potential of human stem cells
N. Biotechnol.
Generation of murine hepatic lineage cells from induced pluripotent stem cells
Differentiation
Identifying developmental toxicity pathways for a subset of ToxCast chemicals using human embryonic stem cells and metabolomics
Toxicol. Appl. Pharmacol.
Automated patch clamp on mESC-derived cardiomyocytes for cardiotoxicity prediction
J. Biomol. Screen.
Back to the future: safety pharmacology methods and models in 2013
J. Pharmacol. Toxicol. Methods
A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS
Cell Stem Cell
EZ spheres: a stable and expandable culture system for the generation of pre-rosette multipotent stem cells from human ESCs and iPSCs
Stem Cell Res.
Direct lineage conversion of terminally differentiated hepatocytes to functional neurons
Cell Stem Cell
Rapid single-step induction of functional neurons from human pluripotent stem cells
Neuron
A cell surfaceome map for immunophenotyping and sorting pluripotent stem cells
Mol. Cell. Proteomics
Primary cells and stem cells in drug discovery: emerging tools for high-throughput screening
Assay Drug Dev. Technol.
Glycosylation of shaker potassium channel protein in insect cell culture and in Xenopus oocytes
Biochemistry
A conditional knockout resource for the genome-wide study of mouse gene function
Nature
Attrition and translation
Science
Modern biomedical research: an internally self-consistent universe with little contact with medical reality?
Nat. Rev. Drug Discov.
Current status of drug screening and disease modelling in human pluripotent stem cells
Bioessays
Human pluripotent stem cells in drug discovery and predictive toxicology
Biochem. Soc. Trans.
Effects of drug transporters on volume of distribution
AAPS J.
Identification of interspecies difference in hepatobiliary transporters to improve extrapolation of human biliary secretion
Expert Opin. Drug Metab. Toxicol.
Embryonic stem cell lines derived from human blastocysts
Science
A guide to drug discovery: target selection in drug discovery
Nat. Rev. Drug Discov.
Target discovery
Nat. Rev. Drug Discov.
Screening for novel LRRK2 inhibitors using a high-throughput TR-FRET cellular assay for LRRK2 Ser935 phosphorylation
PLoS One
How many drug targets are there?
Nat. Rev. Drug Discov.
Thirty years beyond discovery—clinical trials in succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism
J. Inherit. Metab. Dis.
Trial watch: phase II failures: 2008–2010
Nat. Rev. Drug Discov.
Trial watch: phase III and submission failures: 2007–2010
Nat. Rev. Drug Discov.
How were new medicines discovered?
Nat. Rev. Drug Discov.
Cited by (24)
Leveraging the Genetic Diversity of Human Stem Cells in Therapeutic Approaches
2022, Journal of Molecular BiologyCitation Excerpt :In addition to the utility of iPSCs for drug discovery and repurposing, they provide a perfectly suited system for modeling drug toxicity, which often plagues clinical trials and is a main reason for why only 16% of new medicines make it to market.128 Within the brain, iPSC-derived neural cells provide a model way to perform toxicity screens.129,130 Recently, studies have demonstrated neurotoxic effects of ketamine exposure, first in rodents and primates, then recapitulated using iPSC-derived neurons under high concentrations.131,132
Cell-based drug testing; this world is not flat
2014, Advanced Drug Delivery ReviewsStabilized generation of human iPSC-derived liver organoids using a modified coating approach
2023, Biology Methods and ProtocolsRole of stem cells in cancer therapeutics
2020, Handbook of Research on Advancements in Cancer TherapeuticsTox_(R)CNN: Deep learning-based nuclei profiling tool for drug toxicity screening
2018, PLoS Computational Biology
- ☆
This review is part of the Advanced Drug Delivery Reviews theme issue on “Innovative tissue models for drug discovery and development”.